###begin article-title 0
Prognostic Evaluation of Nodal Diffuse Large B Cell Lymphoma by Immunohistochemical Profiles with Emphasis on CD138 Expression as a Poor Prognostic Factor
###end article-title 0
###begin p 1
###xml 877 878 877 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 905 906 905 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 927 928 927 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1081 1082 1081 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 937 945 <span type="species:ncbi:9606">patients</span>
Recently diffuse large B cell lymphoma (DLBCLs) was reported to be subdivided into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subgroups by using cDNA microarray and immunohistochemical markers. Tissue microarray blocks were created from 51 nodal DLBCLs with c ntrol tissue. Immunohistochemical staining for the above markers were performed. The median follow-up period was 26 months. Nodal DLBCLs were subclassified into GCB [CD10+ or CD10-/Bcl-6+/MUM1-, n=17 (33%)] and non-GC subgroups [CD10-/Bcl-6- or CD10-/Bcl- 6+/MUM1+, n=35 (67%)], and were alternatively subclassified into pattern A [+ for GCB marker only, n=12 (23%)], B [Co-positive for both markers, n=13 (33%)], C [+ for activation marker only, n=18 (35%)], and D [- for both markers, n=9 (17%)]. Upon survival analysis, the GCB groups showed a relatively better survival than non-GC groups (p=0.0748). Also, pattern C (p=0.0055) and CD138+ (p=0.0008) patients had significantly lower survival rates. By multivariate analysis, CD138 expression alone was considered as an independent risk factor (p=0.031). In summary, our results add to the registration of prognostic implications for previously reported DLBCL subgroups. CD138 may play an important role as a poor prognostic marker. By using immunohistochemistry, a prognostically important subclassification of DLBCLs is possible.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 477 478 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 612 613 612 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 602 610 <span type="species:ncbi:9606">patients</span>
###xml 659 667 <span type="species:ncbi:9606">patients</span>
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma in Western countries, and accounts for approximately 60% of patients with B-cell lymphomas in East Asia (1,2). Although these tumors are designated as a single disease entity by the World Health Organization (WHO), the diversity of clinical presentations and pathologic, genetic, and molecular characteristics strongly suggest that these neoplasms represent a eterogenous group of tumors (3). Despite the use of anthracyclin-based chemotherapy, long-term disease-free survival can only be achieved in about 40% of patients (1). Therefore, it is important to identify the patients who may benefit from more aggressive or experimental therapies at diagnosis.
###end p 3
###begin p 4
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 308 309 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 580 581 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 551 559 <span type="species:ncbi:9606">patients</span>
Alizadeh et al. recently reported that DLBCL can be divided into prognostically significant subgroups with germinal center B-cell-like (GCB), activated B-cell-like (ABC), or type 3 gene expression profiles using cDNA microarray (3). The GCB group had a significantly better survival rate than the ABC group (3). The type 3 group was heterogeneous and not well defined, but had a poor outcome similar to the ABC group (3). Their results have been confirmed by another study demonstrating that the gene expression profiles predict the survival of DLBCL patients after chemotherapy (4).
###end p 4
###begin p 5
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 368 369 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 370 371 370 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
More recently, there have been several studies subdividing DLBCLs into prognostically important subgroups by using an immunohistochemical panel (5-9). However, the resulting data have been controversial, with several studies showing a significantly better survival rate for the GCB group and others finding no difference in survival between the GCB and non-GC groups (5-9).
###end p 5
###begin p 6
The aim of this study was to investigate the expression of CD10, Bcl-6, MUM1, CD138, and Bcl-2 in nodal DLBCLs, and to analyze the relationship between immunohistochemical profile and outcome in nodal DLBCLs. Thus, we also evaluated the use of an immunohistochemical profile to subdivide DLBCLs into prognostically significant subgroups by using germinal center B-cell (CD10 and Bcl-6) and activation (MUM1 and CD138) markers with a tissue microarray (TMA).
###end p 6
###begin title 7
MATERIALS AND METHODS
###end title 7
###begin title 8
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient population
###end title 8
###begin p 9
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
The study group consisted of 51 patients with de novo nodal DLBCLs including five patients with de novo tonsillar DLBCLs diagnosed at Hanyang University Medical Center from 1995 to 2002, and classified according to WHO criteria based on morphological examination of imprints, paraffin sections, and immunophenotyping.
###end p 9
###begin title 10
Tissue microarray and immunohistochemical staining
###end title 10
###begin p 11
###xml 613 620 609 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
Hematoxylin and eosin-stained sections from each paraffin-embedded, formalin-fixed block were used to define diagnostic areas. In addition, two random, representative 0.6 mm cores were obtained from each case and inserted in a grid pattern into a recipient paraffin block using a tissue arrayer (Beecher Instruments, Silver Spring, MD, U.S.A.). For the control group, three cases of follicular lymphoma and three cases of reactive tonsil were included in each TMA block. Four-microm sections were then cut from each TMA block and stained with antibodies to CD10, Bcl-6, MUM1, CD138, Bcl-2, and MIB1, as listed in Table 1, using the avidin-biotin method. Each core was evaluated independently by two pathologists for the percentage of tumor cells stained by visual estimation, and recorded in 10% increments. Disagreements were resolved by joint review on a multihead microscope. For each case, the core with the highest percentage of stained tumor cells was used for analysis. For CD10, Bcl-6, Bcl-2, MUM-1 and CD 138, cases were considered positive if 30% or more of the tumor cells were stained with an antibody based on previous studies.
###end p 11
###begin title 12
Subgrouping methods of DLBCLs
###end title 12
###begin p 13
###xml 230 237 230 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 241 242 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 702 703 702 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
###xml 441 449 <span type="species:ncbi:9606">patients</span>
Immunoperoxidase results for CD10, Bcl-6, MUM1, and CD138 were used to subclassify the patients. We divided the DLBCLs into subgroups according to two different methods proposed by Hans et al. and Chang et al., which are shown in Table 2 (8,9). According to Hans et al., patients were separated into GCB and non-GC groups (8). If CD10 was positive, regardless of Bcl-6, MUM-1 or Bcl-6 status, DLBCLs were subclassified as GCB. The remaining patients were classified as non-GC. However, according to Chang et al. method, the cases could be subclassified into four patterns: positive GCB marker only (A), positive GCB and activation marker (B), positive activation marker only (C), and all negative (D) (9).
###end p 13
###begin title 14
Statistical analysis
###end title 14
###begin p 15
###xml 638 639 638 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 686 687 684 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 176 184 <span type="species:ncbi:9606">Patients</span>
The Kaplan-Meier method was used to estimate overall survival distributions. Overall survival was calculated from the time from diagnosis to the date of death or last contact. Patients who were alive at last contact were censored in the overall survival analysis. The log-rank test was used to compare the clinical characteristics between the TMA subgroups. Univariate and multivariate analysis was performed using the Cox regression method. Stepwise selection was used to determine variables that were independent predictors of overall survival. The SPSS 11.0 Statistical software (U.S.A.) program was used for data analysis. A value of p<0.05 was considered as significant and 0.05</=p<0.10 as relatively significant.
###end p 15
###begin title 16
RESULTS
###end title 16
###begin title 17
Clinical data
###end title 17
###begin p 18
###xml 32 39 32 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
Clinical data are summarized in Table 3, which represent patients in GCB and non-GC subgroups. Clinical data for survival analysis were available for 51 patients with a minimum follow up period of 16 months. There were 30 males and 21 females with a median age of 59 yr (age range, 19-83 yr). The median follow up period was 26 months. The clinical features of the two DLBCL subgroups (GCB vs. non-GC) did not differ in any regard. Similarly, of the four patterns (A, B, C, and D) observed, clinical parameters did not differ (data not shown).
###end p 18
###begin title 19
Expression of CD10, Bcl-6, CD138, MUM1, and Bcl-2
###end title 19
###begin p 20
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 69 76 <span type="species:ncbi:9606">patient</span>
###xml 201 209 <span type="species:ncbi:9606">patients</span>
###xml 282 290 <span type="species:ncbi:9606">patients</span>
###xml 314 321 <span type="species:ncbi:9606">patient</span>
###xml 445 453 <span type="species:ncbi:9606">patients</span>
Out of the total 51 patients, 11 (22.0%, except for one undetermined patient) were positive for CD10, 20 (39.2%) for Bcl-6, 23 (45.1%) for Bcl-2, 16 (31.4%) for MUM1, and 8 (15.7%) for CD138. When the patients were subdivided according to the two different methods stated above, 21 patients (42.0%, except for one patient with undetermined CD10 status) were subclassified as GCB and 29 (58.0%) as non-GC. Using the four group classification, 17 patients (33.3%) were subclassified as pattern A, seven (13.7%) as B, 14 (27.5%) as C, and 13 (25.5%) as D.
###end p 20
###begin title 21
Survival analysis
###end title 21
###begin p 22
###xml 104 105 104 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 114 121 114 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1A</xref>
###xml 240 241 240 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 250 257 250 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1B</xref>
###xml 353 354 353 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 363 370 363 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2A</xref>
###xml 509 510 509 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 519 526 519 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2B</xref>
###xml 625 626 625 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 785 786 785 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
###xml 490 498 <span type="species:ncbi:9606">patients</span>
Tumor expression of CD10 was associated with better overall survival, which was relatively significant (p=0.0992, Fig. 1A). On the other hand, tumor expression of Bcl-6 also tended to convey better survival, but not to a significant level (p=0.2509, Fig. 1B). MUM1 expression did not result in any difference in overall survival between the two groups (p=0.5207, Fig. 2A). In contrast, CD138 positive patients showed a strikingly worse overall survival rate, although there were only eight patients in total (p=0.0008, Fig. 2B). No significant difference in survival was found between the Bcl-2 positive and negative groups (p=0.5307, not shown). In view of the International Prognostic Index, the low IPI group showed a better survival, which was relatively significant in our study (p=0.0978, data not shown).
###end p 22
###begin p 23
###xml 163 164 163 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 173 180 173 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3A</xref>
###xml 331 332 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 341 348 341 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3B</xref>
###xml 371 372 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 381 388 381 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3C</xref>
###xml 708 715 708 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4A</xref>
###xml 784 791 784 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4B</xref>
###xml 813 820 813 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4C</xref>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
###xml 765 773 <span type="species:ncbi:9606">patients</span>
###xml 838 846 <span type="species:ncbi:9606">patients</span>
When we divided patients into GCB and non-GC subgroups, the GCB subgroup showed a better survival rate than the non-GC subgroup at a relatively significant level (p=0.0748, Fig. 3A). When separately considering patients with low or high IPI scores, the GCB groups also had a better survival rate than the non-GC subgroup with low (p=0.5307, Fig. 3B) and high IPI scores (p=0.1534, Fig. 3C). On the other hand, when we divided the patients into patterns A, B, C, and D, pattern C showed a strikingly poor survival. In contrast, there were no remarkable differences among patterns A, B, and D. When we divided them into two groups, pattern C had a significantly lower survival rate compared to pattern A or B (Fig. 4A). Furthermore, when separately considering those patients with low (Fig. 4B) or high IPI scores (Fig. 4C), four pattern C patients with high IPI scores had a strikingly lower survival than others.
###end p 23
###begin p 24
###xml 215 222 215 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">Table 4</xref>
###xml 569 576 569 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">Table 5</xref>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
By univariate Cox proportional hazards regression analysis, our results showed that expression of the individual CD138 marker and pattern C was associated with an increased relative risk of death in DLBCL patients (Table 4). Moreover, CD 10 expression, GCB subgroup classification, and IPI scores made relatively significant impacts on survival. Most importantly, using a multivariate Cox proportional hazards regression analysis, only the expression of CD138 alone was statistically significant as an independently poor prognostic factors, controlling for IPI status (Table 5).
###end p 24
###begin title 25
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Characteristics of patients with CD138 expression
###end title 25
###begin p 26
###xml 170 177 170 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T6">Table 6</xref>
###xml 301 307 301 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 121 129 <span type="species:ncbi:9606">patients</span>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
###xml 255 262 <span type="species:ncbi:9606">patient</span>
###xml 322 329 <span type="species:ncbi:9606">patient</span>
###xml 353 361 <span type="species:ncbi:9606">patients</span>
###xml 443 450 <span type="species:ncbi:9606">patient</span>
###xml 518 525 <span type="species:ncbi:9606">patient</span>
###xml 637 645 <span type="species:ncbi:9606">patients</span>
###xml 697 705 <span type="species:ncbi:9606">patients</span>
###xml 753 761 <span type="species:ncbi:9606">patients</span>
CD138 was expressed in eight of the 51 DLBCL patients. The clinical and immunohistochemical characteristics of all eight patients with CD138 expression are summarized in Table 6. Six patients were negative for germinal center B cell markers. However, one patient was positive for both CD10 and Bcl-6 (Fig. 5), and another patient for Bcl-6 alone. These patients were classified into subgroups B and GCB, respectively. The first 80-yr-old male patient expired six months later. In contrast, the second 28-yr-old female patient, who had received bone marrow transplantation, was still alive at follow up 68 months later. The remaining six patients were subclassified as pattern C and non-GCB. These patients died in a relatively short period. Most of the patients with CD138 expression showed generally high Ki-67 labeling indices.
###end p 26
###begin title 27
DISCUSSION
###end title 27
###begin p 28
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 371 379 <span type="species:ncbi:9606">patients</span>
TMA is a useful and cost-effective tool that allows rapid evaluation of immunohistochemical staining of a large number of tumors simultaneously (10). TMA appears to be particularly useful for the immunohistochemical characterization of malignant lymphomas (10). The TMA immunostaining results have been shown to agree with whole tissue section staining in 86% to 100% of patients (11). When compared with whole section immunohistochemistry, TMA demonstrates superior immunostaining consistency between cases because most cases are located on the same TMA section (10). Quantitation of the staining results is also easier because each tissue core can be completely viewed under one intermediate-power microscopic field. Furthermore, the use of TMA preserves the tissue in the paraffin blocks for future studies. In the present study, we selected two different, relatively well preserved and representative areas from each tumor for use in the TMA blocks. Thus, we could easily and consistently evaluate the immunohistochemical staining results.
###end p 28
###begin p 29
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 768 770 768 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1017 1019 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 798 806 <span type="species:ncbi:9606">patients</span>
The diversity in the clinical presentation, morphology, immunophenotype, and genetic and molecular alterations strongly suggests that DLBCL is a heterogenous group of B-cell lymphomas rather than a single clinicopathologic entity (12-14). The primary site of the lymphoma, either the lymph node or different extranodal territories, has been suggested as a criterion that might distinguish the two different groups of DLBCL, nodal and extranodal, with particular clinicobiological characteristics and different natural history (15,16). However, the current classification of lymphomas is largely based on the clinicopathologic features and, at present, does not take into consideration the primary site of the lymphoma; it is simply regarded as additional information (12). In the present study, 69 patients with primary de novo nodal DLBCLs were selected for a uniform study population. In general, Waldeyer's ring, whose lymphoid tissue is similar to that of the lymph node, is currently included among nodal areas (16). Therefore, we also included seven DLBCLs of the Waldeyer's ring in the present study.
###end p 29
###begin p 30
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 416 417 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 540 541 540 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 783 784 783 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 10 15 <span type="species:ncbi:9606">human</span>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 688 696 <span type="species:ncbi:9606">patients</span>
CD10 is a human membrane associated neutral endopeptidase, and antibodies against CD10 embedded in paraffin sections are available (17). CD10 is expressed in a variety of human tissues, but its expression is restricted in the germinal center cells of reactive lymphoid tissues (17). There have been several studies examining CD10 expression in DLBCLs by immunohistochemistry, but the resulting data are conflicting (6-9,18-24). Chang et al. and Ohshima et al. have reported that CD10 expression is associated with a better DLBCL prognosis (9,19). In contrast, Uherova et al. and Xu et al. have suggested that CD10 expression is associated with poor outcome (21,24). In the present study, patients with CD10 expression showed a better survival rate at a marginally significant level (p=0.0992).
###end p 30
###begin p 31
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 580 581 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 582 583 582 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 584 585 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 586 588 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 730 731 730 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 232 239 <span type="species:ncbi:9606">patient</span>
###xml 621 629 <span type="species:ncbi:9606">patients</span>
Bcl-6 is a zinc-finger protein that acts as a transcriptional repressor and is expressed in germinal center B cells and a subset of CD4+ T cells (25,26). Immunohistochemical studies of Bcl-6 expression and its relationship to DLBCL patient outcomes are limited in number. Hans et al. reported Bcl-6 expression evaluated by immunohistochemistry to be associated with a better prognosis (8). Likewise, other studies have reported that Bcl-6 expression predicts a better overall survival, whereas another study found no difference in overall survival related as to Bcl-6 expression (6,8,9,27). Our results demonstrated that patients with Bcl-6 expression tended to show better survival, but not at a statistically significant level (p=0.2509).
###end p 31
###begin p 32
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 149 157 <span type="species:ncbi:9606">patients</span>
Regarding the prognostic value of Bcl-2 expression in DLBCLs, most studies have shown no difference in prognosis between Bcl-2 positive and negative patients, whereas a recent study by Biasoli et al. suggested that Bcl-2 expression, especially in the high IPI group, is associated with a significantly decreased survival (8,22,28,29). Our results show no difference in survival between Bcl-2 positive and negative groups, similar to the results of most previous studies, except for Biasoli et al. (22).
###end p 32
###begin p 33
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 367 368 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 458 459 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 725 726 725 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 727 728 727 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 448 456 <span type="species:ncbi:9606">patients</span>
###xml 585 593 <span type="species:ncbi:9606">patients</span>
MUM1/IRF-4 (multiple myeloma-1/interferone regulatory factor-4) is a lymphoid specific member of the interferon regulatory factor family of transcription factors, and is normally expressed in plasma cells and a minor subset of germinal center cells (30,31). Studies have shown that MUM1 expression may denote the late stage of germinal center B-cell differentiation (3,30,31). Moreover, Hans et al. reported that MUM1 expression identified non-GCB patients (8). Thus, we used MUM1 as an activated B cell marker in the present study. Prognostic significance of MUM1 expression in DLBCL patients has been limited. Hans et al. and Chang et al. reported that expression of MUM1 is associated with a significantly worse survival (8,9). However, our results demonstrate no difference in survival between MUM1 positive and negative groups.
###end p 33
###begin p 34
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 255 263 <span type="species:ncbi:9606">patients</span>
CD138, also known as syndecan-1, is expressed in antigen-stimulated B cells and denotes terminal differentiation toward plasma cells (32). The clinical significance of CD138 expression in DLBCL patients has not been well documented. In the present study, patients with CD138 expression showed a strikingly worse survival. However, there were only eight CD138 positive cases.
###end p 34
###begin p 35
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 179 180 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 181 182 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 734 735 734 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 938 939 938 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1149 1151 1149 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1378 1379 1378 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1480 1482 1480 1482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1617 1618 1617 1618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1847 1848 1847 1848 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
###xml 593 601 <span type="species:ncbi:9606">patients</span>
###xml 928 936 <span type="species:ncbi:9606">patients</span>
###xml 1361 1368 <span type="species:ncbi:9606">patient</span>
###xml 1507 1515 <span type="species:ncbi:9606">patients</span>
###xml 1639 1647 <span type="species:ncbi:9606">patients</span>
###xml 1803 1811 <span type="species:ncbi:9606">patients</span>
###xml 1986 1993 <span type="species:ncbi:9606">patient</span>
Recently, there have been several efforts to classify DLBCL patients into prognostically implicated subgroups using cDNA microarray and immunohistochemical expression profiles (3,6-9). However, the methods remain controversial. As a part of the efforts to classify DLBCL patients into prognostically implicated subgroups, the present study used an immunohistochemical panel of GCB-cell and activation markers as stated above, such as CD10, Bcl-6, MUM1, and CD 138, on paraffin-embedded tissues. Hans et al. reported that the expression of CD10, Bcl-6, and MUM1 can be combined to divide DLBCL patients into GCB and non-GC subgroups with outcomes similar to that predicted by cDNA microarray analysis as they have previously reported (8). Chang et al. also reported that the expression patterns of CD10, Bcl-6, MUM1/IRF4, and CD138 of GCB cell and activation markers by immunohistochemistry correlate with the prognosis of DLBCL patients (9). Similarly, Biasoli et al. reported that the expression of CD10 could predict a favorable outcome, especially in the low-risk IPI group, and the expression of Bcl-2 was an independent poor prognostic factor (22). In contrast, Colomo et al. reported that a differentiation profile using CD 10, Bcl-6, MUM1, and CD138 was associated with particular clinicopathological features, but was not essential for predicting DLBCL patient outcome (6). More recently, Fabiani et al. reported that CD10 expression in DLBCLs did not influence survival (23). In the present study, patients in the GCB group showed a relatively better overall survival rate than those in the non-GC subgroup (p=0.0748). Similarly, patients subclassified as pattern C (CD10-, Bcl-6-/MUM1+ or CD138+) showed a significantly lower survival rate than pattern A (CD 10+ or Bcl-6+/MUM1-, CD138-) or B patients (CD10+ or Bcl-6+/MUM1+ or CD138+) (p=0.0055). Our results further support that immunohistochemical expression profiles using CD10, Bcl-6, MUM1, and CD138 could predict DLBCL patient outcome.
###end p 35
###begin p 36
###xml 483 490 483 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T6">Table 6</xref>
###xml 896 903 896 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T6">Table 6</xref>
###xml 1538 1540 1538 1540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 496 504 <span type="species:ncbi:9606">patients</span>
###xml 514 522 <span type="species:ncbi:9606">patients</span>
###xml 679 686 <span type="species:ncbi:9606">patient</span>
###xml 737 744 <span type="species:ncbi:9606">patient</span>
###xml 768 776 <span type="species:ncbi:9606">patients</span>
###xml 864 871 <span type="species:ncbi:9606">patient</span>
###xml 873 880 <span type="species:ncbi:9606">patient</span>
###xml 959 966 <span type="species:ncbi:9606">patient</span>
###xml 968 975 <span type="species:ncbi:9606">patient</span>
###xml 1090 1097 <span type="species:ncbi:9606">patient</span>
###xml 1213 1221 <span type="species:ncbi:9606">patients</span>
###xml 1297 1305 <span type="species:ncbi:9606">patients</span>
###xml 1476 1479 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1734 1742 <span type="species:ncbi:9606">Patients</span>
###xml 2119 2127 <span type="species:ncbi:9606">patients</span>
###xml 2176 2181 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
More interestingly, patients with CD138 expression showed a strikingly worse survival. Upon univariate and multivariate analysis, CD138 expression proved to be an independent poor prognostic factor regardless of IPI status. Even though expression pattern C proved to be an independent poor prognostic factor, it was largely influenced and dependent on CD 138 expression. Thus, its prognostic importance needs to be mentioned in conjunction with that of CD138 expression. As shown in Table 6, six patients of eight patients showing CD138 expression were negative for germinal center B cell markers. Thus, they were subclassified into the non-GC and pattern C groups. However, one patient was positive for both CD10 and BCL-6, and another patient for BCL-6 alone. These patients were subclassified into the GCB and pattern B groups. In particular, an 80 yr-old male patient (patient 1) as shown in Table 6 expired at six months. In contrast, a 28-yr-old female patient (patient 2) was still alive at follow up 68 months later. After a more detailed search for clinical information about this patient, the authors discovered that she received bone marrow transplantation after her DLBCL diagnosis. The remaining six patients in the non-GC and pattern C groups all expired in relatively short period (patients 3-8). Colomo et al. reported that CD138 is highly expressed in the plasmablastic variant of DLBCL, the so-called plasmablastic lymphoma, which is usually associated with HIV infection, and has a highly aggressive clinical behavior (33). Plasmablastic lymphoma was characterized by immunoblastic morphology and a plasma cell phenotype with absent or weak B-cell markers and strong reactivity for plasma cell associated antigens. Patients with CD138 expression in the present study might be diagnosed with plasmablastic lymphoma. However, all eight CD138 expression tumors did not show the morphologic criteria of plasmablastic lymphoma upon histologic review. They were also diffusely and strongly positive for B-cell markers such as CD20 and CD79a. Moreover, despite a diligent search for clinical records of all patients with CD138 expression, there was no evidence of HIV-1 infection or immunosuppression. Thus, the possibility of plasmab lastic lymphoma having an aggressive clinical behavior could be ruled out. Therefore, our results suggest that CD138 expression may play an important role in clinical outcome as a poor prognostic factor. Unfortunately, CD138 expression has been reported at an extremely low expression rate, as shown by the present study.
###end p 36
###begin p 37
###xml 261 269 <span type="species:ncbi:9606">patients</span>
###xml 465 473 <span type="species:ncbi:9606">patients</span>
In conclusion, our results add to the registration of prognostic implications of previously reported DLBCL subgroups. In addition, CD138 may play an important role as a poor prognostic marker. Further investigations examining CD138 expression that include more patients are necessary to reach more specific conclusions. Finally, by using an immunohistochemical panel for CD10, BCL-6, MUM-1, and CD138 expression, prognostically important subclassification of DLBCL patients was attained.
###end p 37
###begin p 38
###xml 48 66 48 66 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hanyang University</funding-source>
###xml 68 77 68 77 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HY-2003-S</award-id>
###xml 80 98 80 98 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2004-000-0000-1202</award-id>
This work was supported by a research fund from Hanyang University (HY-2003-S & 2004-000-0000-1202).
###end p 38
###begin article-title 39
The Non-Hodgkin's Lymphoma Classification Project
###end article-title 39
###begin article-title 40
Diffuse large cell lymphoma
###end article-title 40
###begin article-title 41
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
###end article-title 41
###begin article-title 42
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
###end article-title 42
###begin article-title 43
###xml 105 112 <span type="species:ncbi:9606">patient</span>
Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma
###end article-title 43
###begin article-title 44
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma
###end article-title 44
###begin article-title 45
Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study
###end article-title 45
###begin article-title 46
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
###end article-title 46
###begin article-title 47
Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma
###end article-title 47
###begin article-title 48
Immunohistochemical analysis of B-cell lymphoma using tissue microarrays identifies particular phenotypic profiles of B-cell lymphomas
###end article-title 48
###begin article-title 49
Tissue micro-array: a cost and time-effective method for correlative studies by regional and national cancer study groups
###end article-title 49
###begin article-title 50
Diffuse large B-cell lymphoma
###end article-title 50
###begin article-title 51
Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification
###end article-title 51
###begin article-title 52
Current trends in large cell lymphoma
###end article-title 52
###begin article-title 53
Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation; a population-based study of 1575 cases
###end article-title 53
###begin article-title 54
Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin
###end article-title 54
###begin article-title 55
CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas
###end article-title 55
###begin article-title 56
Histologic and immunohistologic findings and prognosis of 40 cases of gastric large B-cell lymphoma
###end article-title 56
###begin article-title 57
CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis
###end article-title 57
###begin article-title 58
CD10 expression in primary intestinal large B-cell lymphomas: its clinical significance
###end article-title 58
###begin article-title 59
The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma
###end article-title 59
###begin article-title 60
###xml 101 109 <span type="species:ncbi:9606">patients</span>
CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses
###end article-title 60
###begin article-title 61
Groupe d'Etudes des Lymphomes de l'Adulte. CD10 expression in diffuse large B-cell lymphomas does not influence survival
###end article-title 61
###begin article-title 62
Comparison of multiparameter flow cytometry with cluster analysis and immunohistochemistry for the detection of CD10 in diffuse large B-Cell lymphomas
###end article-title 62
###begin article-title 63
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry
###end article-title 63
###begin article-title 64
BCL-6 protein is expressed in germinal-center B cells
###end article-title 64
###begin article-title 65
Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas
###end article-title 65
###begin article-title 66
Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma
###end article-title 66
###begin article-title 67
Rearrangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas
###end article-title 67
###begin article-title 68
A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells
###end article-title 68
###begin article-title 69
MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies
###end article-title 69
###begin article-title 70
Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease
###end article-title 70
###begin article-title 71
Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities
###end article-title 71
###begin p 72
###xml 59 60 59 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 84 85 84 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 89 90 89 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 176 177 176 177 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 92 100 <span type="species:ncbi:9606">Patients</span>
###xml 179 187 <span type="species:ncbi:9606">Patients</span>
Kaplan-Meier survival analysis in DLBCL according to CD10 (A) and Bcl-6 expression (B). (A) Patients with CD10 expression above 30% demonstrate significantly better survival. (B) Patients with Bcl-6 expression above 30% tend to have a relatively better survival, but not at a significant level.
###end p 72
###begin p 73
###xml 59 60 59 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 84 85 84 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 89 90 89 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 188 189 188 189 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 191 199 <span type="species:ncbi:9606">Patients</span>
Kaplan-Meier survival analysis in DLBCL according to MUM1 (A) and CD138 expression (B). (A) MUM1 expresssion does not influence the overall survival between positive and negative groups. (B) Patients with CD138 expression show a strikingly worse overall survival, although there were only eight positive cases.
###end p 73
###begin p 74
###xml 75 76 75 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 153 154 153 154 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 156 157 156 157 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 279 280 279 280 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 309 310 309 310 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
Kaplan-Meier survival analysis in DLBCL between GCB and non-GC subgroups. (A) The GCB subgroup demonstrates a longer survival than the non-GC subgroup. (B, C) When separately considering patients with low or high IPI scores, the GCB groups possess a longer survival in both low (B) and high IPI score groups (C).
###end p 74
###begin p 75
###xml 69 70 69 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 190 191 190 191 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 193 194 193 194 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 334 335 334 335 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 364 365 364 365 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 230 238 <span type="species:ncbi:9606">patients</span>
Kaplan-Meier survival analysis in DLBCL among patterns A, B, and C. (A) The overall survival rate curve of pattern C shows a significantly lower survival rate compared to patterns A and B. (B, C) When separately considering those patients with low or high IPI scores, pattern C also shows a strikingly poor survival rate in both low (B) and high IPI score groups (C).
###end p 75
###begin p 76
###xml 99 100 99 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 143 144 143 144 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 146 147 146 147 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 149 150 149 150 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 152 153 152 153 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 202 203 202 203 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 210 211 210 211 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 226 227 226 227 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 247 248 247 248 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 80 87 <span type="species:ncbi:9606">patient</span>
###xml 131 138 <span type="species:ncbi:9606">patient</span>
###xml 262 269 <span type="species:ncbi:9606">patient</span>
Histologic and immunohistochemical findings of an 80-yr-old male CD138 positive patient (case 1). (A) Histologic findings of DLBCL patient 1. (B, C, D, E) Tumor cells were diffusely positive for CD138 (B: x40, C: x200), CD10 (D: x200), and BCL-6 (E: x200). This patient died within six months.
###end p 76
###begin p 77
Antibodies used for immunohistochemical staining
###end p 77
###begin p 78
Subgrouping methods for DLBCLs
###end p 78
###begin p 79
###xml 31 39 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of 76 patients with diffuse large B-cell lymphomas and statistical comparison between GCB and non-GC subgroups
###end p 79
###begin p 80
Stt, Student t-test; Srt, Spearman's rho test
###end p 80
###begin p 81
Univariate Cox proportional hazards regression analysis
###end p 81
###begin p 82
RR, Relative risk.
###end p 82
###begin p 83
Multivariate Cox proportional hazards regression analysis
###end p 83
###begin p 84
RR, Relative risk.
###end p 84
###begin p 85
###xml 11 19 <span type="species:ncbi:9606">patients</span>
Summary of patients with CD138 expression
###end p 85
###begin p 86
###xml 56 57 56 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 64 71 <span type="species:ncbi:9606">patient</span>
GC/NG, GCB subgroup vs. non-GC subgroup. FU, follow-up. *, This patient received bone marrow transplantation for treatment.
###end p 86

